PETReA Plus
Research type
Research Study
Full title
Prospective observational study of treatment & outcomes for patients with newly diagnosed follicular lymphoma
IRAS ID
352809
Contact name
Kim Linton
Contact email
Sponsor organisation
University of Liverpool
Duration of Study in the UK
4 years, 6 months, 1 days
Research summary
Follicular lymphoma (FL) is the most common low grade or slow growing blood cancer. It affects white blood cells called B lymphocytes. FL usually responds well to treatment, but advanced stage (disseminated disease) cannot yet be cured. More treatment is needed when the disease comes back (relapses). The aims of treatment are to control symptoms and delay relapse for as long as possible. For most people initial treatment controls FL for many years and life expectancy is near normal, but in around 20-30% of cases the disease relapses more quickly or transforms to high grade (aggressive) lymphoma leading to shorter survival. It is not yet possible at the time of diagnosis to predict who will undergo an early relapse of FL or transform. Identifying these high-risk patients is an important research challenge and the key to developing better treatments to improve outcomes and reduce the cumulative burden and toxicity of re-treatment.
PETReA Plus is an observational study aimed at addressing gaps in knowledge that may be important for improving outcomes by helping clinicians to choose the most effective therapy for individual patients and design the next generation of clinical trials for personalised care, and to support regulatory approvals of new treatments. The study is linked to PETReA, an ongoing international trial evaluating PET scan guided treatment in FL for better outcomes. PETReA Plus will collect information on treatment and outcomes from 500 people undergoing any initial treatment for FL to complement results of PETReA. Participants will have the opportunity to contribute their data to the Follicular Lymphoma Foundation Precision Medicine Registry, which is part of a global programme to improve the speed and development of new treatments and ultimately to cure FL.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
25/EE/0092
Date of REC Opinion
7 May 2025
REC opinion
Further Information Favourable Opinion